Length of Diagnostic Delay in Patients with Non-small-cell Lung Cancer

被引:0
|
作者
Valdes, Solangel [1 ]
Garcia, Eberto [1 ]
Perez, Hayvin [1 ]
Hernandez, Marisela [1 ]
机构
[1] Hosp Neumol Benef Jurid, Havana, Cuba
关键词
Lung cancer; non-small-cell lung carcinoma; diagnosis; delivery of health care; SYMPTOMS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Despite advances in diagnostic techniques and treatment, lung cancer is the leading cause of cancer death worldwide and in Cuba. Prompt initiation of cancer therapy depends on rapid diagnostic confirmation; however, most patients are diagnosed at an advanced stage. In the Cuban health system, primary, secondary and tertiary levels of care are interrelated; patients may seek care at any level or may be referred from one to another. Lung cancer diagnoses are confirmed at the tertiary level. Objective Determine the length of diagnostic delay in patients diagnosed with non-small-cell lung cancer (NSCLC) at a tertiary care facility in Havana, Cuba, as well as mean diagnostic delay attributable to the patient and to the health system by level of care. Methods A descriptive observational study of 96 patients with a cytologically and/or histologically confirmed diagnosis of non-small-cell lung cancer was conducted in 2005-2007. Patients initially sought care for disease symptoms at primary, secondary or tertiary levels in the Cuban public health system, but diagnosis of all patients was confirmed at a specialized tertiary care facility. Total diagnostic delay was calculated as the time elapsed from onset of symptoms to confirmation of NSCLC diagnosis. Variables also included diagnostic delay attributable to the patient and diagnostic delay attributable to the health system by level of care. Data were arranged in tables and analyzed by absolute value, percentage, mean, and standard deviation. Results Of the 96 patients studied, 69% were male, and 54% were aged 50-69 years. Fifty-five percent of patients sought medical care within 15 days of onset of symptoms, 21% within 16-30 days, and 3% waited >90 days. Mean diagnostic delay attributable to the patient was 18.19 +/- 3.45 days while mean diagnostic delay attributable to the health system was 61.63 +/- 18.50 days, and overall diagnostic delay was 73.13 +/- 17.53 days. For the 71% of patients seen in primary care, mean diagnostic delay was 29.51 +/- 4.53 days; for the 45% seen exclusively or additionally at the secondary level, mean diagnostic delay was 24.45 +/- 7.31 days. Upon admission at the tertiary care level, mean diagnostic confirmation delay was 18.23 +/- 3.68 days. Conclusions Diagnostic delay of lung cancer patients in this study was prolonged. Appropriate strategies are needed for reducing this delay.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [31] Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma
    Shiran, Iris
    Heller, Eyal
    Jessel, Shlomit
    Kamer, Iris
    Daniel-Meshulam, Inbal
    Navon, Rossie
    Urban, Damien
    Onn, Amir
    Bar, Jair
    CLINICAL LUNG CANCER, 2017, 18 (03) : 316 - +
  • [32] Avelumab in non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET ONCOLOGY, 2018, 19 (11): : 1423 - 1424
  • [33] Diagnostic value of serum dihydrodiol dehydrogenase 2 levels in patients with non-small-cell lung cancer
    Xu, Chun-Hua
    Ren, Ding-Yu
    Wang, Yu-Chao
    Zhang, Qian
    Zhang, Xiu-Wei
    Qian, Li-Hua
    Shao, Jie-Bao
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2018, 33 (04): : 475 - 481
  • [34] Radiochemotherapy in non-small-cell lung cancer
    Swartman, B.
    Hausmanns, J.
    Zwicker, F.
    Thomas, M.
    Herfarth, K.
    Heussel, C. P.
    MEDIZINISCHE KLINIK, 2011, 106 (03) : 212 - 217
  • [35] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
  • [36] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [37] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [38] LncRNAs in Non-Small-Cell Lung Cancer
    Ginn, Lucy
    Shi, Lei
    La Montagna, Manuela
    Garofalo, Michela
    NON-CODING RNA, 2020, 6 (03)
  • [39] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    PET CLINICS, 2018, 13 (01) : 1 - +
  • [40] Erlotinib in non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Malone, Paolo
    Colantuoni, Giuseppe
    Del Gaizo, Filomena
    Ferrara, Carmine
    Nicolella, Dario
    Guerriero, Ciro
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2579 - 2592